Biotech Is Place to Be for Top Salaries
May 09 2019 - 10:02AM
Dow Jones News
By Patrick Thomas
In biotechnology, the rank and file are well-to-do.
Many of the highest-paying employers in the health-care sector
-- and the entire S&P 500 -- were biotech companies, according
to an analysis by The Wall Street Journal of annual disclosures for
hundreds of big U.S. companies as provided by MyLogIQ.
New Jersey-based Celgene Corp., which sells a treatment of
multiple myeloma, had the highest-paid median employee in the
sector and S&P 500 at $263,237. Celgene was followed by
Boston-based Vertex Pharmaceuticals Inc., which makes treatments
for cystic fibrosis and infectious diseases, paying its typical
worker $232,178.
Biotech firms typically have smaller employee populations and
rely on skilled medical and scientific researchers.
Vertex has roughly 2,300 employees, most of which are based in
the U.S., and Celgene has about 7,000 workers. Vertex declined to
comment beyond its proxy. Celgene didn't respond to requests for
comment.
The Wilmington, Del., drugmaker Incyte Corp., which has about
1,400 employees, said its median worker made $228,006. An Incyte
spokeswoman said most of its employees work in research and
development. The company doesn't have any manufacturing employees,
who tend to have lower salaries, she said.
Incyte's median employee has a bachelor's degree and more than
three years of experience, the spokeswoman said. The employee's
compensation is made up of salary, yearly bonus, stock awards and
benefits, she said.
Gilead Sciences Inc., which had one of the largest employee
populations of the highest-paying biotech firms, with 10,500
workers, reported that its median employee was paid $163,963.
Gilead Sciences declined to comment.
Health-care equipment and services companies typically had
lower-paid median workers compared with their biotech peers. CVS
Health Corp., which sells health insurance and medical software in
addition to operating its pharmacy chain, had one of the
lowest-paid median workers, at $35,529. A spokesman for the company
said unlike health-care companies that report a higher median
compensation, CVS operates a large retail business that employs
many part-time, temporary and seasonal workers.
The company has roughly 230,000 employees and 9,900 retail
stores, according to its latest proxy filing.
Other health-care companies with lower-paid median workers
typically had more employees based overseas in manufacturing
roles.
Medical-device maker Align Technology Inc. had the lowest median
pay in the sector at $13,180. While the company has 11,700
employees, only 1,400 are in the U.S., according to its latest
proxy filing. The company identified its median employee as an
associate engineer in a manufacturing facility in Mexico.
A spokeswoman for Align said 60% of its employees have
manufacturing jobs in such lower-wage regions as Latin America and
China. She added that the company believes its overall compensation
is competitive within each region.
Most publicly traded U.S. firms are disclosing their median
employee pay for a second straight year, along with compensation
for top executives. Firms must include part-time and temporary
workers, but not contractors, and have the option of annualizing
pay for some midyear hires and excluding midyear acquisitions.
Companies may exclude up to 5% of their global workforce, but
only non-U.S. workers, and may use sampling techniques to identify
the median employee.
The Journal analysis, based on data from MyLogIQ for more than
1,300 companies, focused on the health-care sector as defined by
S&P Global. The sector includes industry groups encompassing
pharmaceutical, biotechnology, life-science and health-care
equipment and services companies.
Check out this interactive link for the full ranking of
companies or to search for a specific company or industry.
--Theo Francis contributed to this article.
Write to Patrick Thomas at Patrick.Thomas@wsj.com
(END) Dow Jones Newswires
May 09, 2019 09:47 ET (13:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024